ArticleDiscover oncology2026
Systemic inflammatory indices as accessible biomarkers for intracranial outcome and prognosis in driver gene-negative NSCLC with brain metastases treated with first-line chemoimmunotherapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFor patients with driver gene-negative non-small cell lung cancer (NSCLC) with brain metastases, chemoimmunotherapy represents the standard treatment. However, the intracranial objective response rate (iORR) remains limited, highlighting the need for effective predictive biomarkers. This study aimed to evaluate the predictive value of systemic inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR). These indices were assessed for their ability to predict intracranial response and survival among these patients.
methodsThis dual-center retrospective cohort study enrolled 94 driver gene-negative NSCLC patients with brain metastases receiving first-line chemoimmunotherapy. Optimal cutoff values for NLR, PLR, and LMR for predicting iORR were determined by ROC analysis. Associations with iORR, overall survival (OS), and progression-free survival (PFS) were assessed using logistic and Cox regression.
resultsHigh NLR (P = 0.001) and high PLR (P = 0.001) were associated with lower iORR, while high LMR predicted higher iORR (P = 0.001), with an AUC of 0.774. In multivariate analysis, LMR was an independent prognostic factor for OS in the overall population (HR = 0.538, P = 0.032). Notably, in the subgroup receiving intracranial radiotherapy (n = 74), LMR retained its independent prognostic significance.
conclusionsPretreatment systemic inflammatory indices, particularly LMR, serve as simple and effective predictive biomarkers for intracranial response and long-term survival in driver gene-negative NSCLC patients with brain metastases treated with first-line chemoimmunotherapy. These findings provide a clinical basis for early identification of high-risk patients and may guide individualized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.